Mater Misericordiae Hospitals, South Brisbane, Australia B cell chronic lymphocytic leukaemia (CLL) shows evidence of familial aggregation, but the inherited basis is poorly understood. Mutations in the ATM gene have been demonstrated in CLL. This, coupled with a possibly increased risk of leukaemia in relatives of patients with Ataxia Telangiectasia, led us to question whether the ATM gene is involved in familial cases of CLL. To examine this proposition we typed five markers on chromosome 11q in 24 CLL families. No evidence for linkage between CLL and ATM in the 24 families studied and the best estimates of the proportion of sibling pairs that share no, one or both haplotypes at ATM were not different from their null expectations. This would imply that ATM is unlikely to make a significant contribution to the three-fold increase in risk of CLL seen in relatives of patients.
Introduction
In western countries leukaemia affects approximately 1-2% of the population. 1 Of the many subtypes, B cell chronic lymphocytic leukaemia (CLL) is the most common, constituting about 30% of all cases. 2 Its incidence rate increases logarithmically from age 35 and has a median age of diagnosis at 65 years. 3 Epidemiological studies strongly suggest that CLL and other lymphoproliferative disorders (LPDs) have an inherited component. There are over 40 reports in the literature describing the clustering of CLL sometimes in association with other LPDs. 4 Few of these families are multigenerational. The transmission of CLL in these families is most parsimonious with an autosomal dominant mode of inheritance with incomplete penetrance. 5 Five case-control studies and one cohort study have found that the risk of leukaemia or other LPD in relatives of lymphocyctic leukaemia patients is increased three-fold (reviewed in Ref. 5) . Although none of these studies has systematically examined the familial risk of leukaemia by specific subtype, it is likely that the familial risk of leukaemia in relatives of lymphocytic leukaemia patients reflects an increased risk of CLL since acute lymphoblastic leukaemia does not display an increased sibling risk. 6 The genetic basis of CLL is largely unknown. Cytogenetic abnormalities are less frequent in CLL than in many other haematological malignancies. 7 A number of chromosome breakage syndromes are associated with an increased risk of leukaemia 8 including the recessive disease Ataxia Telangiectasia (A-T). A-T maps to chromosome 11q23. 9 A-T patients have an increased risk of lymphomas and leukaemias, while A-T heterozygotes have a significantly increased risk of breast cancer. 10 CLL has also been reported in A-T families.
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The ATM gene specifies a 12 kb mRNA encoding an ෂ350 kDa protein. 12, 13 The 3Ј end of the gene has some homology to phosphinositide 3-kinases and to S. cerevisiae TEL1 that controls telomere length and maintenance of genome integrity.
14 Homozygous germline mutations in ATM are associated with radiosensitivity and genomic instability: the mutation rate is increased; 15 double-strand breaks are misrepaired; 16 there is a high frequency of cytogenetic rearrangements; 17 homologous recombination is increased and errorprone. 18 A-T cells also show defects in cell cycle checkpoints. 19 These defects underlie a model 20 in which the Atm protein functions to survey the genome for radiation damage.
It has been demonstrated that the ATM gene is mutant in approximately 20% of samples from CLL patients and that some patients have heterozygous germline mutations. 21, 22 This and the prevalence of leukaemia in relatives of patients with A-T led us to question whether germline ATM mutations are involved in familial cases of CLL. In this study, we examined this proposition by undertaking an analysis for linkage at chromosome 11q23 in families with CLL.
Materials and methods

Patient selection
Twenty-four families with multiple family members affected with CLL were ascertained by haematologists in the United Kingdom, Norway, Israel, Italy, Ireland, Germany, Portugal, The Netherlands and Australia. The diagnoses of B-CLL in family members were established in all cases by established criteria. Samples were obtained with informed consent and ethical review board approval. DNA was salt extracted from EDTA blood samples using a standard sucrose lysis method.
Genotyping
PCR reactions were performed at the following microsatellite loci: D11S2371, D11S2022, D11S2000, D11S1998 and D11S4464. PCR primer sequences were taken from the Marshfield database (http://genetics.mfldclin.end). DNA was amplified by PCR in a 15 l reaction, annealing at 55°C in 1.5 mm MgCl 2 . Dye-labelled PCR products were detected on ABI 377 DNA sequencers and analysed using Genescan and Genotyper software (Warrington, UK).
Statistical methods
Linkage of CLL to chromosome 11q was first assessed by parametric LOD-score analysis, based on a population carrier frequency of mutations in the ATM gene of 0.01 under a dominant model of inheritance. 11 In the absence of a precise model, phenocopy rates of 80% and 95% were used to encompass the range of possible dominant models predicted from the data recently published by Stankovic et al. 22 All unaffected individuals were classified as of unknown phenotype. This allows for the possibility than an apparently unaffected individual may actually be affected and ensures that false negative data are not generated. The analysis was carried out using the program GENEHUNTER. 23 Multipoint heterogeneity LOD (HLOD) scores were computed over chromosome 11q defined by D11S2371 and D11S4464. The program also determines non-parametric linkage on the basis of non-model-dependent haplotype sharing. Results are summarised in terms of a statistic, Z, which estimates the excess (over that expected by chance) haplotype sharing, divided by its s.d., under the null hypothesis of no linkage. Statistical significance is assessed by relating Z to a standard normal distribution. To assess the contribution of genes on 11q to siblings with CLL, haplotype sharing among affected sibling pairs was also assessed, by use of the program MAPMAKER/SIBS, 24 with the 'all pairs' option. The allele sharing probabilities of affected sibling pairs (ASPs) depend on the contribution any gene makes to the genetic variation of the trait. The 0, 1 and 2 sharing probabilities are given by: 1/4 s , o /2 s , and mz /4s; 25 where s , o and mz are the sibling, offspring and monozygotic relative risks. These formulae hold true irrespective of the mode of inheritance at the disease locus, the number of alleles and their frequencies, penetrance and population prevalence of disease. Using the allele sharing probabilities amongst ASPs, the relative risk of CLL associated with the ATM locus can be derived from the 0 sharing prob- 
Results
Twenty-four CLL families detailed in Table 1 were used in the linkage analysis. Families 42 and 65 had other family members affected with another LPD. Table 2 shows the LOD scores for linkage of CLL to 11q23 microsatellite markers. The markers D11S2000 and D11S1998 flank the ATM gene by 8 cM and 4 cM, respectively. These provide no evidence for linkage of CLL to 11q23 markers in these families. The overall HLOD score, for all 24 families, was 0.00. No support for linkage was detected at ATM by adjusting the phenocopy rate from 80% to 95%. The non-parametric analysis by the program GENEHUNTER found no significant evidence for linkage to ATM. The affected-sibling-pair MAPMAKER/SIBS analysis showed that the best estimates of the proportion of sibling pairs that share no, one, or both haplotypes at ATM were their null expectations (ie 0.25, 0.50 and 0.25). This implies that ATM is unlikely to account for more than a 1.9-fold increase in risk of CLL in siblings. Based upon this range of sibling relative risk, under a dominant model of transmission and with a population A-T carrier frequency of 0.01, the genotypic risk of CLL attributable to ATM will be less than 20. 
Discussion
We undertook this linkage analysis of chromosome 11q to determine whether ATM was implicated in familial CLL for two reasons. Firstly, germline mutations can be demonstrated in ATM in samples from apparently sporadic CLL patients. 21, 22 Secondly, there is some prior epidemiological evidence for ATM as a CLL predisposition gene. In a retrospective study of the cancer incidence in 110 A-T families 11 the risk of haematological and lymphoid malignancies was increased in blood relatives of A-T patients and CLL accounted for all but one of the leukemias seen in adult blood relatives. However, neither of these observations was statistically significant.
Multigenerational families are characteristic of highly penetrant susceptibility genes. Less than 5% of CLL is familial and nearly all are nuclear. 5 Multigenerational CLL families have rarely been observed. 5, 26 It is therefore conceivable that genes that confer susceptibility to CLL do so with more modest risks. Within this class of genes, ATM represents a credible candidate predisposition locus for CLL.
In our study, we found no evidence to support the involvement of the ATM gene in familial CLL. However, the range of genotypic risks compatible with the observed distribution of sharing of ATM haplotypes between affecteds is large. Stankovic et al 22 observed two germline ATM mutations in 32 cases (6.3%) of CLL (P = 0.04; 95% CI: 1-21%). Assuming that 6.3% of CLL is caused by ATM, 22 mutations in this gene should only confer a sibling relative risk of 1.1. On this basis our families have limited power to demonstrate linkage between ATM and CLL. To preclude involvement of the ATM gene as a predisposition locus for CLL requires studies based upon larger sets of families and cases.
